MENU
BMRN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

BMRN stock forecast, quote, news & analysis

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases... Show more

Industry: #Biotechnology
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for BMRN with price predictions
Nov 04, 2026

BMRN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for BMRN turned positive on October 20, 2026. Looking at past instances where BMRN's MACD turned positive, the stock continued to rise in 33 of 50 cases over the following month. The odds of a continued upward trend are 66%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMRN's RSI Oscillator exited the oversold zone, 18 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.

The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on BMRN as a result. In 54 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.

Following a +4.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRN advanced for three days, in 162 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 65 cases where BMRN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.

BMRN broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BMRN entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. BMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.749) is normal, around the industry mean (2.904). BMRN's P/E Ratio (154.405) is considerably higher than the industry average of (-0.738). Projected Growth (PEG Ratio) (0.348) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (3.727) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.27B. The market cap for tickers in the group ranges from 58 to 139.16B. VRTX holds the highest valuation in this group at 139.16B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -14%, and the average quarterly price growth was -21%. CRIS experienced the highest price growth at 144%, while KPTI experienced the biggest fall at -91%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -5%. For the same stocks of the Industry, the average monthly volume growth was -12% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 46
Price Growth Rating: 66
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
BMRN's MACD Histogram just turned positive